Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
86.8M
-
Shares change
-
+4.83M
-
Total reported value, excl. options
-
$2.19B
-
Value change
-
+$105M
-
Put/Call ratio
-
1.19
-
Number of buys
-
86
-
Number of sells
-
-56
-
Price
-
$25.24
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2020
180 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q4 2020.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86.8M shares
of 226M outstanding shares and own 38.36% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (18.7M shares), Capital Research Global Investors (12.6M shares), Capital International Investors (7.13M shares), BlackRock Inc. (6.47M shares), VANGUARD GROUP INC (5.79M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.56M shares), STATE STREET CORP (3.37M shares), ALLIANCEBERNSTEIN L.P. (2.59M shares), Capital World Investors (2.37M shares), and JPMORGAN CHASE & CO (1.96M shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.